ACCOUNTS - Final Accounts

ACCOUNTS - Final Accounts

AMYNEPHARMA LIMITED - Company Information

Print Friendly Version

Caseware UK (AP4) 2018.0.111 2018.0.111 2018-10-312018-10-31The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.truetrueNo description of principal activityfalse2017-11-01 07798764 2017-11-01 2018-10-31 07798764 2016-11-01 2017-10-31 07798764 2018-10-31 07798764 2017-10-31 07798764 c:CompanySecretary1 2017-11-01 2018-10-31 07798764 c:Director1 2017-11-01 2018-10-31 07798764 c:RegisteredOffice 2017-11-01 2018-10-31 07798764 d:ComputerEquipment 2017-11-01 2018-10-31 07798764 d:ComputerEquipment 2018-10-31 07798764 d:ComputerEquipment 2017-10-31 07798764 d:ComputerEquipment d:OwnedOrFreeholdAssets 2017-11-01 2018-10-31 07798764 d:CurrentFinancialInstruments 2018-10-31 07798764 d:CurrentFinancialInstruments 2017-10-31 07798764 d:CurrentFinancialInstruments d:WithinOneYear 2018-10-31 07798764 d:CurrentFinancialInstruments d:WithinOneYear 2017-10-31 07798764 d:ShareCapital 2018-10-31 07798764 d:ShareCapital 2017-10-31 07798764 d:RetainedEarningsAccumulatedLosses 2018-10-31 07798764 d:RetainedEarningsAccumulatedLosses 2017-10-31 07798764 c:FRS102 2017-11-01 2018-10-31 07798764 c:AuditExemptWithAccountantsReport 2017-11-01 2018-10-31 07798764 c:FullAccounts 2017-11-01 2018-10-31 07798764 c:PrivateLimitedCompanyLtd 2017-11-01 2018-10-31 iso4217:GBP xbrli:pure

Registered number: 07798764










AMYNEPHARMA LIMITED








UNAUDITED

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 OCTOBER 2018
 
AMYNEPHARMA LIMITED
 

COMPANY INFORMATION


DIRECTOR
A HIOUNI 




COMPANY SECRETARY
M HIOUNI



REGISTERED NUMBER
07798764



REGISTERED OFFICE
930 HIGH ROAD

LONDON

N12 9RT




ACCOUNTANTS
BAGINSKY COHEN
CHARTERED ACCOUNTANTS

930 HIGH ROAD

LONDON

N12 9RT




 
AMYNEPHARMA LIMITED
 

CONTENTS



Page
Accountants' report
 
 
1
Balance sheet
 
 
2
Notes to the financial statements
 
 
3 - 7

 
AMYNEPHARMA LIMITED
 
  
CHARTERED ACCOUNTANTS' REPORT TO THE DIRECTOR ON THE PREPARATION OF THE UNAUDITED STATUTORY FINANCIAL STATEMENTS OF AMYNEPHARMA LIMITED
FOR THE YEAR ENDED 31 OCTOBER 2018

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Amynepharma Limited for the year ended 31 October 2018 which comprise  the Balance sheet and the related notes from the Company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at http://www.icaew.com/en/ members/regulations-standards-and-guidance/.

This report is made solely to the director of Amynepharma Limited in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the financial statements of Amynepharma Limited and state those matters that we have agreed to state to the director of Amynepharma Limited in this report in accordance with ICAEW Technical Release TECH07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Amynepharma Limited and its director for our work or for this report. 

It is your duty to ensure that Amynepharma Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Amynepharma Limited. You consider that Amynepharma Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or review of the financial statements of Amynepharma Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

  

BAGINSKY COHEN
 
CHARTERED ACCOUNTANTS
  
930 HIGH ROAD
LONDON
N12 9RT
28 February 2019
Page 1
 
AMYNEPHARMA LIMITED
REGISTERED NUMBER: 07798764

BALANCE SHEET
AS AT 31 OCTOBER 2018

2018
2018
2017
2017
Note
£
£
£
£

FIXED ASSETS
  

Tangible assets
 4 
1,500
938

  
1,500
938

CURRENT ASSETS
  

Debtors: amounts falling due within one year
 5 
287
2,590

Cash at bank and in hand
 6 
274,800
306,516

  
275,087
309,106

Creditors: amounts falling due within one year
 7 
(27,504)
(30,159)

NET CURRENT ASSETS
  
 
 
247,583
 
 
278,947

TOTAL ASSETS LESS CURRENT LIABILITIES
  
249,083
279,885

  

NET ASSETS
  
249,083
279,885


CAPITAL AND RESERVES
  

Called up share capital 
  
100
100

Profit and loss account
  
248,983
279,785

  
249,083
279,885


The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 28 February 2019.

A HIOUNI
Director

The notes on pages 3 to 7 form part of these financial statements.

Page 2
 
AMYNEPHARMA LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2018

1.ACCOUNTING POLICIES

 
1.1

BASIS OF PREPARATION OF FINANCIAL STATEMENTS

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

 
1.2

FOREIGN CURRENCY TRANSLATION

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

 
1.3

REVENUE

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
∙the amount of revenue can be measured reliably;
∙it is probable that the Company will receive the consideration due under the contract;
∙the stage of completion of the contract at the end of the reporting period can be measured reliably; and
∙the costs incurred and the costs to complete the contract can be measured reliably.

 
1.4

INTEREST INCOME

Interest income is recognised in the Statement of comprehensive income using the effective interest method.

Page 3
 
AMYNEPHARMA LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2018

1.ACCOUNTING POLICIES (CONTINUED)

 
1.5

TAXATION

Tax is recognised in the Statement of comprehensive income, except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

 
1.6

TANGIBLE FIXED ASSETS

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, on a reducing balance basis.

Depreciation is provided on the following basis:

Computer equipment
-
25%
reducing balance

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in the Statement of comprehensive income.

 
1.7

DEBTORS

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
1.8

CASH AND CASH EQUIVALENTS

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
1.9

CREDITORS

Short term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

Page 4
 
AMYNEPHARMA LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2018

1.ACCOUNTING POLICIES (CONTINUED)

 
1.10

FINANCIAL INSTRUMENTS

The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in non-puttable ordinary shares.

 
1.11

DIVIDENDS

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.


2.



JUDGMENTS IN APPLYING ACCOUNTING POLICIES AND KEY SOURCES OF ESTIMATION UNCERTAINTY

In the application of the company’s accounting policies, which are described in note 1, management is required to make judgments, estimates and assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods. 


3.


EMPLOYEES

The average monthly number of employees, including directors, during the year was 1 (2017 - 1).

Page 5
 
AMYNEPHARMA LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2018

4.


TANGIBLE FIXED ASSETS





Computer equipment

£



COST OR VALUATION


At 1 November 2017

3,889


Additions
1,062



At 31 October 2018

4,951



DEPRECIATION


At 1 November 2017
2,952


Charge for the year on owned assets
500



At 31 October 2018

3,452



NET BOOK VALUE



At 31 October 2018
1,499



At 31 October 2017
938


5.


DEBTORS

2018
2017
£
£


Trade debtors
20
2,590

Other debtors
267
-

287
2,590



6.


CASH AND CASH EQUIVALENTS

2018
2017
£
£

Cash at bank and in hand
274,800
306,516


Page 6
 
AMYNEPHARMA LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2018

7.


CREDITORS: Amounts falling due within one year

2018
2017
£
£

Trade creditors
30
27

Corporation tax
2,080
5,720

Other taxation and social security
-
652

Other creditors
13,746
12,062

Accruals and deferred income
11,648
11,698

27,504
30,159



Page 7